Protagonist Therapeutics announced that an abstract for its Phase 3 VERIFY study of rusfertide in polycythemia vera was accepted for presentation at the Plenary Session of the American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO meeting is scheduled to be held from May 30 to June 3, 2025.
The selection for a Plenary Session is a prestigious honor, indicating that the study's findings are considered to have exceptional scientific merit and significant potential to impact cancer care. This highlights the compelling nature of the rusfertide data.
Dr. Andrew T. Kuykendall is listed as the presenting author for this important session. The announcement builds anticipation for the detailed presentation of the rusfertide Phase 3 data, following earlier positive topline results.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.